Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Technologies Thought Leader Award Supports Translational Research Program

Published: Monday, March 04, 2013
Last Updated: Monday, March 04, 2013
Bookmark and Share
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.

Agilent Technologies Inc. announces that Dr. Ronald A. DePinho, a world-renowned oncologist and researcher, has received an Agilent Thought Leader Award. DePinho is president of the University of Texas MD Anderson Cancer Center.

DePinho and his team hope to discover and characterize alterations in metabolic flux during tumor initiation and maintenance, and to identify biomarkers for early detection of pancreatic cancer together with novel therapeutic targets. Researchers on his team will work with scientists from the university’s newly formed Institute of Applied Cancer Sciences.

The Agilent Thought Leader Award provides funds to support personnel as well as a state-of-the-art Agilent 6550 iFunnel Q-TOF LC/MS system.

“I am extremely pleased to receive this award for metabolomics research, as the survival rates for pancreatic cancer have not significantly improved over the past 20 years,” DePinho said. “This technology will allow us to rapidly identify new targets that drive the formation, progression and maintenance of pancreatic cancer. Discoveries from this research will also lead to the development of effective early detection biomarkers and novel therapeutic interventions.”

“We are proud to support Dr. DePinho’s exciting translational research program, which will make use of metabolomics and integrated biology workflows and solutions in biomarker discovery,” said Patrick Kaltenbach, Agilent vice president and general manager of the Liquid Phase Division. Kaltenbach is also the executive sponsor of this award.

“The ability to investigate in a comprehensive, unbiased manner the metabolic adaptations that occur during the development of pancreatic cancer will be greatly enhanced by this [Agilent 6550 iFunnel Q-TOF LC/MS] instrument,” said Dr. Giulio Draetta, director of the Institute for Applied Cancer Science. “The insights gained from these studies will allow us to understand the changes that occur during the evolution of pancreatic cancer. Armed with novel biomarkers, earlier diagnosis and treatment will be possible, leading to improved patient outcomes. Additional opportunities for novel therapeutic intervention will also emerge from this work.”

The Agilent Thought Leader Program promotes fundamental scientific advances by contributing financial support, products and expertise to the research of influential thought leaders in the life sciences and chemical analysis fields. 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies Teams with University of Liverpool's Centre for Genomic Research
Centre for Genomic Research has become the UK's first Certified Service Provider for the Agilent SureSelect Target Enrichment System for next-generation sequencing.
Wednesday, August 08, 2012
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Completes Acquisition of Dako, Danish Cancer Diagnostics Company
Acquisition to help strengthen Agilent's position in life sciences.
Thursday, June 28, 2012
Agilent to Acquire Dako for $2.2 Billion
The largest acquisition in Agilent’s history is the next step in their growing role in clinical diagnostics.
Friday, May 18, 2012
Agilent Appoints Molecular Genomics as its First Certified Service Provider for Microarrays in Singapore
Molecular Genomics offers microarray services using the Agilent CGH/SNP microarrays, gene expression, and microRNA products.
Monday, July 25, 2011
Agilent Appoints BGI First Certified Service Provider in China for Target Enrichment System for Next-Gen Sequencing
Certified for all SureSelect XT target enrichment protocols including human all-exon, SureSelect indexing, DNA capture, RNA capture, kinome RNA and custom kits.
Sunday, April 17, 2011
Agilent Technologies Acquire Lab901
Agilent Technologies Inc. announces that it has acquired the Edinburgh-based electrophoresis equipment and consumables company, Lab901.
Thursday, March 03, 2011
Agilent Debuts RNA Target Enrichment, Streamlining Transcriptome Profiling Studies to Advance Cancer and Stem Cell Research
Company has introduced SureSelect RNA Capture Kits, enabling geneticists to focus on specific genomic loci or transcripts of research interest.
Wednesday, February 09, 2011
Agilent Technologies Extends Million-Feature Format to Gene Expression Microarrays
Agilent SurePrint G3 Gene Expression Microarrays provides up to one million features per standard 1-by-3-inch slide for added throughput.
Tuesday, May 18, 2010
Automating Viral RNA Genotyping
Agilent Automation Solutions has released a new applications bulletin that describes an automated system for rapid characterization of pathogens, including for example the Influenza A (H1N1) virus.
Thursday, February 18, 2010
Agilent Technologies and Covaris Sign Co-Marketing Agreement
The agreement is aimed at pairing target enrichment with DNA shearing for next-gen sequencing.
Wednesday, January 06, 2010
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos